tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Latest News

Nuvilex Investors Watch as Incyte Shares Rise Sharply on Pancreatic Cancer Trials Data

Nuvilex Investors Watch as Incyte Shares Rise Sharply on Pancreatic Cancer Trials Data

Written by ι Stock Market Media Group Staff — August 28, 2013

As Nuvilex, Inc. (OTCQB: NVLX) continues to methodically build its brand as a biotechnology firm ahead of its future Phase III clinical trials for the treatment of advanced, inoperable pancreatic cancer, it looks on while one more big pharmaceutical company produces inferior data to its own.  This time it’s Incyte Corporation, a $5.5 billion market cap company that just enjoyed a more than $10 rise in its share price to over $37/share after positive data was announced for its mid-phase pancreatic cancer clinical trials.

Another clinical trial, another big pharmaceutical company, and another positive outcome for Nuvilex shareholders as the company, once again produces better clinical trials data than the competition.  Incyte investors rewarded the company’s work with a 30% increase in its share price. 

So, what is Nuvilex truly worth considering it’s currently priced at less than $0.135 per share and its mid-phase data is better than any data produced by Incyte, Celgene, Infinity Pharmaceuticals, and even Eli Lilly, whose pancreatic cancer drug, Gemzar (gemcitabine), is the industry’s “gold standard” and the only drug approved by the FDA as a single agent for the treatment of advanced, inoperable pancreatic cancer.

In commenting on Incyte’s clinical trial results, Nuvilex’s COO, Dr. Gerry Crabtree, stated “The excitement engendered within the investment community upon publication of Incyte’s mid-phase clinical trial data, as manifested by a 30% increase in that company’s share price, serves to add impetus to all of us at Nuvilex in our pursuit of further clinical studies with our pancreatic cancer treatment.  The fact that data such as that from Incyte’s trial do not appear to surpass that obtained in our mid-phase clinical trials, only reinforces our belief that, in the future, our treatment will help those who suffer from advanced pancreatic cancer, one of the deadliest and most difficult-to-treat forms of the disease.”

Let’s compare Nuvilex to the latest company releasing pancreatic cancer clinical trials results:

Incyte’s study used a combination of two drugs – their drug Jakafi plus the well-known anticancer drug capecitabine (Xeloda).  In Nuvilex’s mid-phase trials for pancreatic cancer, the Company’s unique and proprietary cellulose-based live-cell encapsulation technology was used together with a single long-used anticancer drug, ifosfamide.

Incyte’s study compared the Jakafi-capecitabine combination with capecitabine plus placebo, according to a description of the study on the National Institute of Health’s www.clinicaltrials.gov website.

And, according to the company press release, Incyte is reporting that the 6-month survival rate for the Jakafi-capecitabine combination was 42%.  This figure represents only 6 months of data, meaning if one were to extrapolate those numbers out to a one-year survival rate, it could reasonably be expected that a significantly lower figure would result.  In Nuvilex’s mid-phase pancreatic cancer trials, the one-year survival rate was 36%.  With the number already extrapolated out to one-year, it’s clear to see that Nuvilex’s one-year survival rate would likely be substantially greater than Incyte’s with the additional calculations.

The Incyte trial reported serious side effects – 12% of all patients treated with the Jakafi-capecitabine combination were discontinued from the study.  In the mid-phase trials using Nuvilex’s pancreatic cancer treatment, no drug-related side effects were reported.

As is becoming commonplace, Nuvilex’s data is strong enough through two independent Phase II clinical trials, to stand on its own and so far above all others.

0
ContactUs.com